Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Prognosis
131 results:

  • 1. [colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
    Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
    [No Abstract]    [Full Text] [Related]  

  • 2. Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced colorectal cancer Patients: An Exploratory Study.
    Cayún JP; Cerpa LC; Colombo A; Cáceres DD; Leal JL; Reyes F; Gutiérrez-Cáceres C; Calfunao S; Varela NM; Quiñones LA
    Curr Oncol; 2024 Jan; 31(1):274-295. PubMed ID: 38248103
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
    Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
    Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after Treatment Termination.
    Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
    Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
    Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
    Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Small molecular inhibitors for KRAS-mutant cancers.
    Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
    Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Rapid Reduction of CEA and Stable Metastasis in an
    Kubota Y; Han Q; Morinaga S; Tsunoda T; Hoffman RM
    In Vivo; 2023; 37(5):2134-2138. PubMed ID: 37652473
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
    Li J; Zeng Q; Lin J; Huang H; Chen L
    Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Novel applications of histopathological markers to distinguish prognostic subgroups in colorectal adenocarcinoma.
    Yuan Y; Ren W; Zhu J; Ji S; Yang Q
    Ann Med; 2023; 55(2):2244181. PubMed ID: 37557892
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.
    Li N; Lin P; Zuo Z; You MJ; Shuai W; Orlowski R; Manasanch EE; Li S; Xu J; Garces S; Jelloul FZ; Tang Z; Wang W; Medeiros LJ; Yin CC
    Cancer Med; 2023 Jul; 12(13):14293-14304. PubMed ID: 37212518
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. SMARCB1/INI1-Deficient Poorly Differentiated Carcinoma of the Colon With Rhabdoid Features-A Rare Tumor With Serrated Phenotype: Case Report and Review of Literature.
    Maurya S; Yadav S; Bhowmik S; Dhal J; Mehra L; Sharma R; Krishna A; Sharma A; Barwad A; Das P
    Int J Surg Pathol; 2024 Feb; 32(1):187-195. PubMed ID: 37128676
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic Impact of Ras Mutation on Surgical Strategy in Rectal cancer Patients Undergoing Neoadjuvant Treatment.
    Orlandi E; Romboli A; Citterio C; Trubini S; Vecchia S; Palladino MA; Capelli P; Cavanna L
    Anticancer Res; 2023 May; 43(5):2015-2024. PubMed ID: 37097644
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases.
    Fassi E; Mandruzzato M; Zamparini M; Bianchi S; Petrelli F; Baggi A; Alberti A; Grisanti S; Berruti A
    Lung Cancer; 2023 May; 179():107176. PubMed ID: 37015149
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Prognostic Value of
    Asako K; Hayama T; Hashiguchi Y; Miyata T; Fukushima Y; Shimada R; Kaneko K; Nozawa K; Matsuda K; Fukagawa T
    Anticancer Res; 2023 Apr; 43(4):1563-1568. PubMed ID: 36974804
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. European expert panel consensus on the clinical management of BRAF
    Martinelli E; Arnold D; Cervantes A; Stintzing S; Van Cutsem E; Tabernero J; Taieb J; Wasan H; Ciardiello F
    Cancer Treat Rev; 2023 Apr; 115():102541. PubMed ID: 36931147
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. KRAS, nras, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.
    Bhattacharya S
    Crit Rev Oncol Hematol; 2023 Mar; 183():103916. PubMed ID: 36717006
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis.
    Zhang M; Meng L; Zhang Z; Wu J; Chen X; Wang Y; He J
    BMC Med Genomics; 2022 Dec; 15(1):259. PubMed ID: 36517805
    [TBL] [Abstract] [Full Text] [Related]  


    of 7.